Full Press Release Details
Abeona Therapeutics Announces Third Quarter
2016 Financial Results and Recent Clinical Highlights
Conference Call to be held Friday, November 18 at 10:30 am ET
NEW YORK, NY and CLEVELAND, OH -
November 10, 2016 -- Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical
company focused on developing therapies for life-threatening rare genetic diseases, today announced financial results for
the third quarter. The Company will provide investors an update on recent and ongoing business activities and an overview of its
3Q16 financials on, Friday, November 18 at 10:30 am (Eastern). Interested parties are invited to participate in the call by dialing
877-269-7756 (toll free domestic) or 201-689-7817 (international).
"During the third quarter of 2016,
we have made significant progress advancing our clinical gene therapy programs addressing serious genetic diseases and showcased
the strengths of our clinical and regulatory capabilities. Notably, we demonstrated promising safety and bio-potency in the low-dose
cohort for ABO-102 and received Fast Track designation for the program and Orphan Drug Designation in the European Union where
we are expanding clinical studies," stated Timothy J. Miller, Ph.D. "In addition, our
strategic work in adding the AIMTM vector platform, an AAV capsid portfolio from University of North Carolina at Chapel
Hill, positions us well for advancing next generation proprietary AAV gene therapies."
Third Quarter Summary Financial Results:
"The third fiscal quarter of 2016
brought significant advancements in our goal of building a strong leadership position in the development of innovative therapies
for rare diseases," stated Steven H. Rouhandeh, Executive Chairman. "We are excited about the initial biopotency signals
seen in our ABO-102 Phase 1/2 clinical trial for Sanfilippo syndrome Type A (MPS IIIA), initiation of the EB-101 Phase 2 study
for epidermolysis bullosa (EB), and the completion of a $42 million financing which provides us with ample runway to continue creating
significant value for the Company and its shareholders."
Abeona Recent Highlights:
Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company
developing gene and plasma-based therapies for life-threatening rare genetic diseases. Abeona's lead programs are ABO- 102 (AAV-SGSH)
and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB, respectively).
Abeona is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for
epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy
for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a
novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein
therapy pipeline, including SDF Alpha (alpha-1 protease inhibitor) for inherited COPD, using its proprietary SDF
(Salt Diafiltration) ethanol-free process. For
more information, visit www.abeonatherapeutics.com.
Christine Berni-Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
Vice President, Communications & Operations
Abeona Therapeutics Inc.
press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933,
as amended, and that involve risks and uncertainties. These statements are subject to numerous risks and uncertainties, including
but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact
of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals;
the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to
time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission.
The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update
them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future
developments or otherwise.